A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
← catalyst calendarSponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
250actual
Sites
27
Countries
Canada, Germany, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-12 | actual | When the study began enrolling |
| Primary completion | 2025-05-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-14 | actual | The whole study's end, after follow-up |
| First posted | 2022-01-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms
- Triple Negative Breast Neoplasms
- HER2 Negative Breast Neoplasms
- Hormone Receptor Positive Breast Neoplasms
- Endometrial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Cholangiocarcinoma
- Gallbladder Carcinoma
- Adenoid Cystic Carcinoma
Interventions
- Drug: Felmetatug Vedotin — also filed as SGN-B7H4V, PF-08046048
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Through 30 days after last study treatment, up to approximately 5 years
Number of participants with laboratory abnormalities
measured Through 30-37 days after last study treatment, up to approximately 5 years
Number of participants with dose limiting toxicities (DLTs)
measured Up to 28 days
Number of participants with dose limiting toxicities (DLTs) and overall safety by dose level
measured Through 30-37 days after last study treatment; up to approximately 5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed